You just read:

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS Program

News provided by

Janssen Inc.

Jun 12, 2017, 21:00 ET